SelankExperimental neuroactive peptide
Selank is a synthetic peptide developed around tuftsin, an immune-related peptide. Its research and marketing focus on anxiety, stress and attention.
What is Selank?
Selank is a synthetic peptide developed around tuftsin, an immune-related peptide. Research and marketing focus on anxiety, stress and attention.
How it works
Proposed actions include GABA-related signalling involved in stress and anxiety. A pathway effect does not establish a measured benefit in an anxiety disorder.
Effects studied
Anxiety-related symptoms
The retained clinical lead includes benzodiazepine-associated treatment. An adjunctive result would not establish the same effect from Selank alone, and small reports leave uncertainty about consistency and effect size. 1
Evidence: Small clinical investigations and laboratory studies
What does the evidence show?
The retained material describes small clinical investigations and laboratory mechanisms. It does not provide a firm basis for broad claims about anxiety treatment or everyday focus.
A molecule with several proposed pathways
Selank has been studied in relation to signalling systems involved in stress and anxiety, including GABA-related pathways. These mechanisms are not interchangeable with the evidence for established anxiety treatments. Demonstrating a change in a biological pathway does not determine how a person feels or functions.
What the clinical comparison needs to show
An anxiety study should define the disorder, distinguish symptom relief from sedation and measure changes against a suitable comparator. The archive includes a report involving benzodiazepine treatment. A finding about adjunctive use would not establish the same effect from Selank alone. 1
Why the evidence stays specific
Small studies can identify findings worth pursuing while leaving considerable uncertainty about the size and consistency of any benefit. Assessing that evidence requires attention to methods and independent replication. Promotional terms such as “non-addictive” or “natural” cannot resolve the uncertainty, and limited adverse-event reporting does not establish long-term safety.
Selank is not Semax
Selank and Semax are often marketed together, but come from different starting molecules and have different research questions. Evidence for one cannot be counted as evidence for the other. Product identity, formulation and local regulatory status also require separate checks before research findings can inform clinical use.
Safety & status
Limited adverse-event reporting does not establish long-term safety or prove that the compound is non-addictive. Formulation and product identity matter.
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is Selank a form of Semax?
No. Their similar names do not make their biological origins or study evidence interchangeable.
Does an adjunctive study show Selank works on its own?
No. A study alongside another medicine needs a comparison that separates their contributions.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Selank: paper 10.17116/jnevro20151156133-40 Research reference · Retained archive reference; not independently checked for this draft.
- Selank: paper 10.1002/dta.2717 Research reference · Retained archive reference; not independently checked for this draft.
- Selank: paper 10.1007/s10571-009-9432-0 Research reference · Retained archive reference; not independently checked for this draft.
- Selank: www.statnews.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.